Final Communiqué - World Health Organization

1
AFRICAN PROGRAMME FOR ONCHOCERCIASIS CONTROL (APOC)
Eleventh Session of the Joint Action Forum (JAF)
Paris, France, 6-9 December 2005
Final Communiqué
1. At the invitation of the Government of France, the Eleventh Session of the Joint Action Forum
(JAF) was held at the Kleber International Conference Center in Paris, France from 6 to 9
December 2005. The meeting was attended by donor countries and institutions, participating
countries, Merck and Co. Inc, Non Governmental Development Organizations (NGDOs), the
Technical Consultative Committee (TCC) of APOC, the West African Health Organization
(WAHO), the External Evaluation Team of APOC, the Mid-Term Review team of the Special
Intervention Zones (SIZ) of the former OCP, the onchocerciasis national coordinators of some exOCP countries, WHO secretariat and APOC Management. A complete list of participants is
attached as Annex 1.
2. In their opening statements, His Excellency, Prof. Emile Bongeli Yeikolo Ya Ato, Honourable
Minister of Health, DRC and Chair of JAF10, and Dr Catherine Le Galès-Camus, representing
the Director-General of WHO, outlined the activities of APOC over the last twelve months. They
expressed their gratitude to the donor community for its continued support to onchocerciasis
control efforts despite the competing demands from other prominent diseases such as HIV/AIDS,
Malaria, Tuberculosis and Avian flu. Both speakers listed the impressive achievements of APOC,
highlighted the challenges facing the Programme and stressed the need to extend the operations of
APOC until 2015 in order to complete the implementation of CDTI projects in a sustainable
manner.
3. The Forum paid tribute to Dr Azodoga Sékétéli, former Director of APOC, for his strong
leadership of APOC over the last 10 years and wished him a happy retirement. The Forum also
congratulated Dr Uche Amazigo on her appointment as new Director of APOC and pledged its
full support to her in her daunting responsibilities.
4. Dr Uche Amazigo underscored the activities of the Programme on which APOC Management
will be focusing attention in the coming months. Among these, the management will aim to:
strengthen the APOC partnership, develop the human resources of the Programme, support
member countries towards strengthening the national health systems, promote integration of other
health interventions through CDTI, review the staffing of APOC Management, continue to
strengthen the capacity of APOC countries in the management of SAEs, and maintain treatment
in conflict areas. She assured JAF that APOC Management will work closely with, and consult,
the APOC partners as much as necessary and will build a strong spirit of teamwork with her
colleagues within APOC Management.
5. Mr Jean-Christophe Deberre, Director, Department of International Policy Development of the
Ministry of Foreign Affairs of France, in his formal opening of the session, welcomed participants
to the meeting and expressed the pleasure of the Government of France to be hosting a meeting of
the onchocerciasis control programmes for a second time in two decades. He thanked the donors
for their continued support to onchocerciasis control, particularly Merck and Co. Inc., for the
2
donation of Mectizan free of charge for as long as needed for the treatment of onchocerciasis
throughout the world.
6. Dr Frédéric Goyet, Director of the Health Bureau of the Ministry of Foreign Affairs, France, was
elected to chair JAF11 and Mrs M.J. Mwaffisi, Permanent Secretary of the Ministry of Health of
the United Republic of Tanzania was elected as Vice-Chair.
7. The provisional agenda attached as Annex 2 was adopted without modifications. However, the
Forum subsequently requested that the agenda of future JAF sessions be reorganized in a manner
to allow for more time for discussions.
8. The reflections of the Committee of Sponsoring Agencies (CSA) were presented by Dr James
Mwanzia, Chairman of the Committee. In his statement, he underscored the main activity
undertaken by the Committee, namely, organizing the External Evaluation of APOC and the Midterm Review of SIZ and the ex-OCP countries. He informed the Forum that a Vision on the future
of APOC had been prepared by CSA and will be presented to JAF for guidance. He also
announced that a Donors' Conference was being planned for June 2006 to formalize the way
forward in implementing the Vision and to mobilize resources for the financial shortfall to
complete APOC. CSA was also proposing to convene a meeting bringing together all 30
onchocerciasis-endemic countries in Africa to discuss the strategy for eliminating onchocerciasis
throughout the continent.
9. CSA called for a concrete debate on integration of CDTI and the neglected tropical diseases to
take place within the onchocerciasis community at large and especially within the endemic
countries.
10. The Forum was informed by the chair of the CSA that a statue was unveiled in October 2005 at
the Royal Tropical Institute in Amsterdam, the Netherlands, in recognition of the unstinting and
steadfast support of the donor community to onchocerciasis control for the past three decades.
11. A video film on onchocerciasis control activities, using Cameroon as an example was projected
which further highlighted some of the achievements and operational challenges facing the
Programme. Among other issues, the Honourable Minister of Health of Cameroon emphasized
the critical role of the community volunteers, the experience in the management of Serious
Adverse Events (SAEs) and the importance of sustainability and efficiency of APOC activities.
He appealed to donors to continue their support to APOC to enable it achieve its objective. He
also welcomed the idea of a proposed Donors' Conference in June 2006.
12. A summary of the discussions of the meeting is presented under the following agenda items. A
full report of the meeting will be made available at a later date.
PROGRESS REPORT OF THE WORLD HEALTH ORGANIZATION, REPORT OF THE
TECHNICAL CONSULTATIVE COMMITTEE AND OF THE NON-GOVERNMENTAL
DEVELOPMENT GROUP FOR ONCHOCERCIASIS CONTROL
13. JAF congratulated APOC Management, the TCC and the NGDO Group on their achievements
over the past year. Having made significant progress in rapid epidemiological mapping of
onchocerciasis (REMO) in DRC, Angola and Sudan, it is estimated that 89 million people are
3
now at risk of contracting onchocerciasis and 37 million people are infected with the disease.
Progress in the implementation of CDTI projects had also allowed for the treatment of over 38
million people through 72 projects under implementation in 2004.
14. To ensure the availability to the public at all times of accurate data on APOC activities, JAF
requested that APOC Management should regularly update APOC data (on e.g. treatments,
blindness, population at risk) in the Weekly Epidemiological Record of WHO.
15. The Forum also remarked that there was need for a gradual decentralization of APOC activities
to participating countries and called on APOC Management to develop a strategy for
decentralization of its activities to the countries. The Forum also requested that APOC
Management establish working relationship with relevant regional organizations which could play
an important role in promoting political and financial commitment of participating countries to
onchocerciasis control activities before and during the Phasing out period of APOC and thereafter.
REPORT OF THE 2005 APOC EXTERNAL EVALUATION
16. The report of the 2005 External Evaluation was presented by Drs Eleuther Tarimo and Bernard
Philippon. The objective of the evaluation was to assess: 1) whether APOC was making progress
towards meeting its 2010 objectives; 2) what measures should be taken to fulfill those objectives;
and 3) how best CDTI activities can be sustained after 2010 to ensure the elimination of
onchocerciasis as a public health problem throughout APOC countries.
17. The evaluation team concluded that, although on the whole, APOC was moving towards the
achievements of its objectives, the target of 2010 will not be achieved because of delays,
particularly related to conflict situations. Consequently, the evaluation team recommended that in
view of the importance of ensuring that all projects are brought to a satisfactory conclusion, the
APOC Trust Fund should be extended to support those projects up to 2015 on a decreasing scale.
The team also made appropriate recommendations for each of the issues they identified.
18. JAF commended the External Evaluation Team for undertaking this important evaluation. The
Forum remarked that the report was received very late by participants who had not had time to
review it. JAF therefore noted the report and requested that comments be sent by e-mail to CSA
which would in turn:
a. reconcile the comments of all partners on the evaluation report;
b. draw up a plan of action based on the outcomes of the evaluation;
c. convene a meeting of partners preferably in an African country in 2006.
19. Nigeria and Cameroon expressed interest in eventually hosting the meeting of partners to be
convened by CSA in 2006.
REPORT OF THE MID-TERM REVIEW OF SPECIAL INTERVENTION ZONES (SIZ) AND EXOCP COUNTRIES
20. Although of interest to all partners, it was clarified that it was not the mandate of JAF to review
the report of the Mid-term Review. JAF however made the following observations on the
presentation of the report:
4
i.
There is a need to ensure that the achievements of OCP are sustained;
ii.
The situation in Sierra Leone requires particular attention and perhaps it would be appropriate to
consider including Sierra Leone in APOC;
iii.
Surveillance is critical to ensuring sustainability of the achievements in ex-OCP countries. The
Multi-Disease Surveillance Centre (MDSC) should be given appropriate support to enable it
provide effective surveillance to all ex-OCP countries;
iv.
There is an urgent need for an intercountry mechanism which should liaise closely with APOC in
overseeing onchocerciasis control activities in ex-OCP countries and throughout Africa;
v.
Advantage should be taken of existing regional organizations to promote policy- related advocacy
for onchocerciasis control;
vi.
Justification for continuing vector control in the SIZ countries was questioned given the high cost
involved. Therefore, although the Mid-term Review team recommended the continuation of
vector control activities, it was suggested that further review be conducted to identify ways of
making savings that could be used to further strengthen CDTI activities in the SIZ countries;
vii.
WHO was strongly encouraged to ensure that its own internal administrative rules regarding staff
contracts do not jeopardize the successful completion (with appropriately trained staff) of the
activities in the SIZ countries.
21. JAF called on WHO and the World Bank to note the observations of JAF and to take appropriate
action.
VISION FOR THE FUTURE OF ONCHOCERCIASIS CONTROL IN AFRICA
22. On the behalf of CSA, Dr. Ousmane Bangoura presented to JAF for guidance a vision paper on
the future of APOC. The vision was based on lessons learnt from implementing OCP and APOC,
opportunities that CDTI could offer to broaden the scope of the formal health systems to reach,
neglected poor populations particularly in remote areas, and ongoing changes in national and
international health priorities. The strategic aim of CSA is to advocate for:
a. strengthening the implementation of onchocerciasis control activities at country level
and for the extension of the duration of APOC beyond 2010, to allow for the full 5
years of financing of CDTI projects whose implementation may have been delayed for
various reasons;
b. broadening the mandate of APOC to include ex-OCP countries;
c. the use of APOC structure as a catalyst for the integration of CDTI with other
appropriate health interventions, especially neglected tropical diseases.
23. JAF requested that a reflection paper be developed by CSA and presented to the proposed 2006
meeting of the partners (see also paragraph 18.c). In this regard, the Forum suggested that a
5
working group, that represents the overall partnership, be set up under the auspices of CSA to
reflect on the following points:
a. The future of the Programme until 2010 including the modalities of an eventual
extension;
b. Modalities of continuing control activities in the countries (transfer, integration,
funding and advocacy);
c. Control of the disease in the whole of Africa: APOC, SIZ areas (after 2007), ex-OCP
countries and countries in conflict situation;
d. Eventual financing on:
i. Current availabilities,
ii. Future projections based on forecasted availabilities and anticipated budgets
after 2010.
24. JAF noted with regret the withdrawal of FAO from CSA. It urged CSA to ensure that UNDP
resume active participation in the activities of CSA. The Forum recognized that the current legal
framework did not allow for a change in the membership of CSA and therefore emphasized the
need for a more active participation of the broader APOC partnership in the discussions of CSA
as may be appropriate.
25. The Forum acknowledged that the CDTI strategy and structure could be utilized to promote
integration of compatible health interventions in the countries thereby pooling synergies and
attracting other partnerships. However, countries should take the lead, eventually with the support
of APOC, in formulating policies on integration based on their individual needs. It was further
emphasized that integration should be at all levels - global, regional, national and community
levels.
26. It was also concluded that APOC is not a vertical programme as it might appear and it was
particularly suitable as a catalyst for integration of health interventions within the national health
systems.
STATEMENTS OF THE PRESIDENTS OF THE "ORGANISATION POUR LA PREVENTION DE LA
CECITE" (OPC) AND OF THE "INSTITUT DE RECHERCHE POUR LE DEVELOPMENT" (IRD),
FRANCE
27. In his address to JAF, Professor Pouliquen, President of the "Organization pour la Prévention de
la Cécité" (Organization for the Prevention of Blindness) recounted the relations of OPC with
onchocerciasis control and the role of NGDOs in APOC activities. He thanked Merck and Co. Inc
and the Mectizan Donation Program (MDP) for donating ivermectin all these years. He also
touched on issues relating to integration, surveillance and motivation of community volunteers as
some of the challenges of CDTI.
28. Professor Girard, President of the "Institut de Recherche pour le Développement" (Research
Institute for Development), outlined the role of IRD in medicine, research and development. He
stressed the relationship between prevention and treatment, between health personnel and the
communities, and the importance of integration and surveillance.
6
29. The Forum expressed appreciation of the participation of Professors Pouliquen and Girard in the
discussions.
COUNTRY REPORTS
30. The Forum acknowledged presentations from DRC, Chad, Equatorial Guinea, Malawi, Republic
of Congo, Uganda, Sudan, Cameroon, Tanzania, Burundi and Angola on their CDTI project
activities. The following issues were common to all or most of the countries:
a. NOTFs recognize that more CDDs need to be recruited and trained in order to reduce
the workload, and existing CDDs should be regularly retrained to maintain/improve
the quality of their work;
b. therapeutic coverage varies from one area to another in most countries partly due to
the fact that CDTI activities are implemented in phases, especially in projects with
hundreds of onchocerciasis-endemic communities or projects in very difficult terrain;
c. governments continue to contribute financially to CDTI activities with increases from
the Governments of Burundi, Cameroon, Chad, Congo, Malawi and Uganda since
2003.
31. As recommended by JAF10, it was reiterated that, in future, countries should present an
integrated budget, i.e. should include the contributions from all partners - governments, NGDOs
and APOC Trust Fund.
32. The attention of the Forum was once again drawn to "nodding disease" and epilepsy and their
possible link with onchocerciasis. JAF requested that TDR should be commissioned to undertake
research on "nodding disease".
CONSIDERATION OF NATIONAL PLANS AND PROJECT PROPOSALS
33. A total of 119 projects have been approved by APOC Management since 1996. In 2005, 2 new
CDTI projects were approved for funding in addition to 54 ongoing projects which submitted
their technical and financial reports to TCC for consideration. An amount of US$3,969,969 had
been requested from the APOC budget for 2006 to fund the 56 projects. The Forum ratified the
requested amount to fund the 56 projects within the overall proposed 2006 budget.
OPERATIONAL RESEARCH AND MACROFIL
34. The Forum was updated on the feasibility study of interruption of transmission with ivermectin
and rapid epidemiological assessment procedure of Loa loa (RAPLOA).
35. The first results of the multi-country study on Community-directed interventions (CDI) were also
presented to JAF which acknowledged the relevance of the study for ongoing discussions on
integration. The Forum was pleased to note that TDR had received a grant of $2.4 million from
the Bill & Melinda Gates Foundation to complete the study.
7
36. The Forum emphasized the need for a safe and effective macrofilaricide for the control of
onchocerciasis.
37. The APOC External Evaluation Team raised concerns, which were echoed by JAF, on the return
on investment made on macrofilaricidal drug research and recommended that Macrofil activities
should be evaluated to assess its processes, prospects of a macrofilaricide and its costeffectiveness.
38. An update on Macrofil activities was presented to the Forum which explained the drug
development process. It was noted that the Phase II clinical trials of moxidectin will be initiated
in the first quarter of 2006 now that the potential safety concerns with one of the veterinarian
products containing moxidectin had been resolved.
39. It was explained that, from the point of view of pharmacokinetic reactions, there were no
concerns regarding the safety of combining ivermectin, praziquantel and albendezole treatments.
It was however cautioned that co-administration of the 3 drugs for the first time in previously
untreated populations should be done only with good monitoring and supervision due to
potentially high parasite burdens in those populations.
SUSTAINABILITY OF CDTI PROJECTS
40. To ensure sustainability, it was stressed that governments should provide sustainable financing
for CDTI activities through PRSPs, HIPC funds and other financing options.
41. JAF stressed that APOC Management should intensify advocacy to ensure that governments
release adequate funds for, and communities contribute towards, critical CDTI activities that drive
sustainability.
42. The need to have a health finance specialist (perhaps seconded from the World Bank) to assist
APOC Management address the issues of governments' financing schemes was emphasized.
43. JAF recognized that community ownership and mobilization were also critical for sustainability
and that sustainability depended to a large extent on integration of CDTI into the national health
system. For example, the Forum noted with pleasure that some CDTI projects in Uganda did not
receive any external funding and were reported to be performing well.
REPORT ON COST PER TREATMENT WITH IVERMECTIN
44. The results of the cost study presented to JAF showed that the cost per treatment with ivermectin
was $0.58. JAF welcomed the study which it felt could be a useful tool for budgeting purposes
and for discussions with donors. The Forum also expressed the need for the cost per treatment to
be calculated separately for projects in conflict zones.
ADDITIONAL HEALTH INTERVENTIONS USING CDTI AS A VEHICLE
45. The Forum requested that APOC Management and countries should share experience on best
practices in integration and the use of CDTI as a vehicle for delivering other health interventions
8
to communities. Although this concept was favourable to the Forum, there were concerns as to
the financing of these additional interventions.
46. The NGDO Group and Merck & Co. Inc. expressed strong reservations on the use of the
ivermectin delivery channel to promote reproductive health related activities.
47. The Forum requested that APOC Management should encourage and continue to support
countries to define national policies on integration and develop strategies for integrating
compatible programmes.
48. The Forum was concerned that other health programmes were providing financial incentives to
CDDs which could jeopardize the CDTI concept. JAF therefore urged participating countries to
define national strategies addressing issues relating to mobilization of, and incentives for,
community volunteers.
INDEPENDENT MONITORING OF CDTI PROJECTS IMPLEMENTATION
49. The Forum was informed that a tool has been developed by APOC Management that enables
projects to independently monitor their CDTI activities (e.g. therapeutic coverage, decisionmaking process, incentives, CDD motivation, ivermectin availability & supply). The tool has
been field tested in Liberia, Cameroon and Nigeria and NOTFs and projects were being
encouraged to utilize it for better planning and management of their CDTI activities.
PHASE II OF THE LONG-TERM IMPACT ASSESSMENT OF APOC OPERATIONS
50. JAF received with pleasure the partial results of the impact assessment and noted that APOC
operations were having significant positive impact on the health of the poor populations. The
Forum however remarked that there might be need to undertake a separate study to assess the
economic impact of APOC operations.
51. The Forum requested APOC to sharpen its focus on results and the impact on the populations
concerned, and consequently to further strengthen surveillance, monitoring and evaluation
activities. The Forum also requested APOC Management to conduct periodic beneficiary
assessments in a sample of projects which would provide timely information on results. JAF
encouraged APOC Management and countries to include in their reporting of APOC activities
impact indicators.
AUDIT REPORT
52. The Forum noted the report of the External Auditor confirming the correctness of the accounts,
receipts and expenditures, which had been submitted for his scrutiny.
PLAN OF ACTION AND BUDGET FOR 2006
53. After a few questions for clarification on the basis of allocation of APOC funds to countries and
on the delays for release of funds to some CDTI projects, the Forum approved the Plan of Action
for 2006 of APOC and the corresponding budget in the amount of US$ 11,249,000.
9
FINANCING OF THE AFRICAN PROGRAMME FOR ONCHOCERCIASIS CONTROL (APOC)
54. The Forum noted that governments of 11 APOC countries contributed a total of US$5,253,000
towards onchocerciasis control activities in 2004. These contributions varied from country to
country and were mostly in the form of staff salaries, cost of training, supervision and monitoring
of CDTI activities.
55. JAF was informed that NGDOs will contribute about $4.6 million towards supporting CDTI
projects in 2006. Although some donors have significantly increased their contributions to APOC,
it was reported that there is still a forecasted funding gap of $9 million in the APOC Trust Fund.
56. The Forum acknowledged with pleasure the financial pledges made by donors who were present
at the meeting. It also reiterated its gratitude to Merck & Co. Inc. which has donated over 1
billion ivermectin tablets worth more than $1.5 billion over the past 15 years.
57. JAF expressed concern on the repeated absence of some donors at APOC meetings and requested
that the World Bank as the fiscal agency should continue its efforts to rekindle the interest of all
existing donors in APOC meetings, Donor Conferences and Programme operations and aim to
attract new donors.
INFORMATION ON THE ACTIVITIES IN THE SPECIAL INTERVENTION ZONES OF THE EXOCP ET NON-SIZ
58. The Forum received an update of the main activities undertaken in the Special Intervention Zones
of ex-OCP countries during the year in the areas of programme management, CDTI, vector
control, epidemiological evaluation, preparation of a strategic document, a joint partners' mission
to Sierra Leone, a workshop on onchocerciasis control in Sierra Leone; and the organization of
the Mid-term Review of SIZ.
59. CDTI activities needed to be reinforced in Ghana and in Sierra Leone; and it was necessary to
improve therapeutic and geographical coverage in Ghana. Epidemiological data had improved in
most cases in Benin and Togo even if there was still need to reinforce control efforts and
strengthen the monitoring system.
60. The main challenges were to maintain support to Sierra Leone during post SIZ period for at least
ten years; maintain or further improve the coverage of ivermectin distribution in all areas until
2012; maintain vector control at a high level of efficacy; ensure sustainable support to
onchocerciasis control and surveillance after SIZ activities end; mobilize funds for increased
technical and financial support to field activities and maintain all technical staff up to the end of
SIZ activities in 2007.
DATE AND PLACE OF JAF12
61. At the invitation of the Government of the United Republic of Tanzania, the twelfth session of
JAF will be held in Tanzania. The date and place will be communicated to participants at a later
date.
10
APPROVAL OF THE CONCLUSIONS AND DECISIONS AND ADOPTION OF THE FINAL
COMMUNIQUE
62. The Forum did not adopt the final communiqué which had been distributed before the end of the
meeting and some of the recommendations had not yet been included in the final draft. It was
therefore agreed that a complete draft be circulated by e-mail to participants for comments.
CLOSURE OF THE SESSION
63. After thanking OPC and the Health Bureau of the French Ministry of Foreign Affairs, for
successfully organizing the meeting, the Chair of JAF expressed his gratitude to all participants
for their active participation in the deliberations and declared closed the 11th session of the Joint
Action Forum.
11
Annex 1
African Programme for Onchocerciasis Control (APOC)
Programme africain de lutte contre l'onchocercose
JOINT ACTION FORUM
Office of the Chairman
JOINT ACTION FORUM
Onzième session
Paris (France), 6-9 décembre 2005
JAF-FAC
FORUM D'ACTION COMMUNE
Bureau du Président
ORIGINAL : FRANCAIS
Décembre 2005
LISTE DES PARTICIPANTS/LIST OF PARTICIPANTS
PAYS/COUNTRIES
Angola
1.
Dr José DIAS VAN-DỨNEM
Vice Ministre, rua 17 de Setembro no 1, Ministère de la Santé, C.P. 1201, Luanda, Angola
Tel : 244 2 37 26 90 - Fax : 244 2 338249 - E-mail : [email protected]
2.
Dr Antonio PEDRO
Coordonnateur National du Programme National de Lutte contre l’Onchocercose, Luanda,
Angola.
Tel : 0044 222 39 67 22 – Fax : 0044 222 39 67 22 – E-mail : [email protected]
Burundi
3.
Dr Libère NDAYISENGA
Coordonnateur National du GTNO, B.P. 1820, Bujumbura, Burundi, Tel : (257) 24 9333 –
Fax : (257) 22 9196 – E-mail : [email protected]
Cameroun
4.
M. Urbain OLANGUENA AWONO
Ministre de la Santé publique, Ministère de la Santé publique, B.P. 155, Yaoundé, Cameroun
Tel : (237) 222 0172 - Fax : (237) 222 02 33
5.
Professeur Assumpta Françoise Lucienne BELLA
Directeur de la Lutte contre la Maladie, Président du GTNO, Ministère de la Santé publique, Yaoundé
Tel : (237) 996 52 86 – Cellulaire : (237) 223 93 48 – Fax : (237) 222 44 19 - E-mail :
[email protected]
6.
Dr Joseph KAMGNO
Conseiller Technique, Loase Cameroun, Ministère de la Santé, B.P. 1274, Yaoundé, Cameroun
Tel : (237) 778 97 36 – Fax : (237) 223 15 64 – E-mail :[email protected]
12
7.
Dr Marcelline NTEP
Coordonnateur National du Programme National de Lutte contre l’Onchocercose, Ministère de la Santé
publique, Tel : (237) 222 69 10 – Fax : (237) 222 69 10 – E-mail : [email protected]
8.
Mme Suzanne EBELLE
Chargée de mission, Services du Premier Ministère, Yaoundé, Cameroun, Tel : (237) 768 60 19 – Fax :
(237) 223 78 80 - E-mail : [email protected]
Congo Brazzaville
9.
Dr Damase BODZONGO
Directeur Général de la Santé, Président du GTNO, Direction Générale de la Santé, B.P. 2101,
Brazzaville, République du Congo
Tel : Dom (254) 81 57 46 Mobile (242) 536 42 77 – Fax : (242) 81 04 81 – E-mail : [email protected]
10.
Dr Charlotte GOKABA OKEMBA
Directrice de la Lutte contre la Maladie, Premier Vice-Président du GTNO, Direction de la Lutte contre
la Maladie, B.P. 236, Brazzaville, Congo, Tel : (242) 551 52 08 – Fax : (242) 81 04 81 –
E-mail : [email protected]
11.
Dr François MISSAMOU
Coordonnateur National du PNLO, Secrétaire Exécutif du GTNO, Direction de la lutte contre la Maladie,
B.P. 236 ou 1066, Brazzaville, Congo, Tel : (242) 668 05 63 – Fax : (242) 81 04 81 –
E-mail : [email protected]
12.
Dr Roland RIZET
Représentant de l’OPC au Congo, Troisième Vice-Président du GTNO, B.P. 13089, Brazzaville,
Tel : (242) 551 58 49, (242)660 68 08 – Fax : (242) 81 58 95, 0047 241 39544 –
E-mail : [email protected]
Guinée Equatoriale/Equatorial Guinea
13.
Dr Nve Justino OBAMA
Ministre de la Santé et du Bien Etre Social, Ministère de la Santé et du Bien Etre Social, Malabo,
Guinée Equatoriale, Tel : (240) 27 38 15 – E-mail : justino@intnet
14.
Dr Nsue Anacleto SIMA
Directeur National, Programme de lutte contre l’Onchocercose et autres Filarioses, Ministère de la Santé
et du Bien Etre Social, Programme Onchocercose et Autres Filarioses, Malabo, Guinée Equatoriale, Tel :
(240) 23 26 20 – Fax : (240) 09 32 36
Kenya
15.
Dr. David SANG
National Coordinator, Division of Vector Borne Diseases, P.O. Box 20750, Nairobi, Kenya
Tel: 722819165 – E-mail: [email protected]
Malawi
16.
Mr Charles Thomson MCHACHA
Deputy Minister of Health, Ministry of Health, P.O. Box 30377, Lilongwe 3, Malawi
Tel: (265) 01 78 94 00/Cellular phone: 265 095 12 63 – Fax: (265) 01788262
13
17.
Dr Storn Binton KABULUZI
Deputy Director of Preventive Health Services, Ministry of Health P.O. Box 30377, Lilongwe 3,
Malawi, Tel: (265) 1 789 424 – Fax: (265) 1 789 424– E-mail: [email protected]
18.
Mr Laston SITIMA
National Onchocerciasis Coordinator, Ministry of Health, P.O. Box 30377, Lilongwe 3, Malawi
Tel: (265) 8 30 34 46 or (265) 1 750 896 – Fax: (265) 1 750 896 – E-mail: [email protected];
[email protected]
19.
Mr Mac Jay SALIJENI
Member of Parliament (MP), P.O. Box 3, Thekerani,Thyolo, Malawi
Tel: (265) 8 396 751
Nigéria/Nigeria
20.
Dr Jonathan Yisa JIYA
National Program Director, Federal Ministry of Health, NOCP Secretariat, Abuja, Nigeria, Tel : (Mobile)
(234) 8034030212, 234 8044184777, Tel/Fax : (Direct number) (234) 9 523 70 49 - Email :
[email protected]; [email protected] - Fax (234) 952 370 49 –
Tél : (234) 952 370 49, E-mail : [email protected]
21.
Ms Immaculata THOMPSON
Personal Assistant to the Honourable Minister for Health, Abuja, Nigeria, Federal Secretariat Phase 3
Abuja, Nigeria
Tel: (234) 09 523 20 48 - Fax: (234) 09 523 70 – E-mail:[email protected]
République démocratique du Congo/Democratic Republic of Congo
22.
Dr Emile BONGELI YEIKOLO YA ATO
Ministre de la Santé, BP 3088, 4310, Boulevard du 30 juin, Kinshasa/Gombe, République démocratique
du Congo, Tel : (243) 998999055/810825155 – Fax : (234) 998 99 9055 –
E-mail : [email protected]
23.
Dr Kupa Marcel MUKENGESHAYI
Coordonnateur National, Programme National de lutte contre l’Onchocercose, Avenue de la Justice No
36, Commune de la Gombe, RDC, Tel : (243) 9999 47 138 –
E-mail : [email protected]; [email protected]
24.
Mme Awezai Béatrice AMISSI
Chargée du partenariat, Ministère de la Santé, 4310, Boulevard du 30 juin, Kinshasa/Gombe
Tel : (242) 9999 29 9083 - E-mail: [email protected]
Soudan/Sudan
25.
Dr Theophillus Ochang LOTTI
Minister of Health, Government of South Sudan, Ministry of Health, Sudan
Tel: (249) 8118 20678 – E-mail: [email protected]
26.
Dr Chor Malek TONG
National Coordinator, Federal Ministry of Health, National Onchocerciasis Control Programme (NOCP),
Khartoum, Sudan, Tel: (249) 912 143820 – Fax: (249) 18378 55 38 –
E-mail: [email protected] or [email protected]
14
27.
Dr Samson Paul BABA
Director for Preventive and Promotive Services, South Sudan Onchocerciasis Control Coordinator
SSOTF, P.O. Box 10114-00100 GPO Nairobi, Kenya, Tel: (254) 722 364982 – Cellular phone: (254)
733 600 647 (Roaming) E-mail: [email protected]; [email protected]
Tanzanie/Tanzania
28.
Mrs Mariam Joy MWAFFISI
Permanent Secretary, Ministry of Health, P.O. Box Box 9083, Dar-es-Salaam, Tanzania
Tel: (255) 22 211 3077 – Fax: (255) 22 2130009 – E-mail: [email protected]
29.
Dr Raphael B.M. KALINGA
Ag. Director Preventive Services, Chair of NOTF, Ministry of Health, P.O. Box 9083, Dar-es-Salaam,
Tanzania, Tel: (255) 22 2113077/21 22 406/7 – Fax: (255) 22 2130009 –
E-mail:[email protected]
30.
Dr Grace SAGUTI
National Coordinator, Eye Care and Onchocerciasis Control, P.O. Box 9083, Dar-es-Salaam, Tanzania,
Tel: (255) 22 2130009 – Fax: (255) 22 2130009 – E-mail: [email protected] or
[email protected]
Tchad/Chad
31.
M. Naoundangar DJEDOSSOUM
Secrétaire Général Adjoint, Ministère de la Santé publique, B.P.440, N’Djaména, Tchad
Tél : (235) 51 40 64 ou 28 99 20 -Fax : (235) 52 48 38 – E-mail :
32.
M. Nadjilar LOKEMLA
Coordonnateur du Programme National de Lutte contre l’Onchocercose, B.P. 4057, N’Djaména, Tchad,
Tél/fax : (235) 52 48 38 – E-mail :[email protected]
Ouganda/Uganda
33.
Dr. Richard NDYOMUGYENYI
National Onchocerciasis Coordinator, P.O. Box 1661, Kampala, Uganda, Tel: (256) 41 348332– Fax:
(256) 41 348332 – E-mail: [email protected]; [email protected]
DONORS/DONATEURS
Banque Africaine de Développement/African Development Bank
34.
Dr Mohamed Mohsen CHAKROUN
Analyste Supérieur en Santé, B.P. 323, 1002 Tunis-Belvedere, Tunisie, Tel : (216) 71 10 25 11 – Fax :
(216) 71 33 36 48 – E-mail : [email protected]
Banque Mondiale/The World Bank
35.
M. Alexandre V. ABRANTES
Sector Manager, AFTH2, The World Bank, 1818 H Street, NW, Washington DC 20043, Tél: (202) 473
0056 –
Fax: (202) 473 8216 – E-mail: [email protected]
15
36.
Dr Ousmane BANGOURA
Onchocerciasis Unit Coordinator, The World Bank,1818 H Street, NW, Washington D.C 20043, Tél: (202)
373 4004 – Fax: (202) 373 8216 – E-mail: [email protected]
37.
Dr Bernhard LIESE
Public Health Specialist (Consultant), Onchocerciasis Coordination Unit, The World Bank,1818 H Street,
NW, Washington DC 20433, Tél: (202) 458 4491 – Fax: (202) 473 8216 – E-mail: [email protected]
38.
Ms Tshiya SUBAYI-CUPPEN
Operations Officer, Onchocerciasis Coordination Unit, The World Bank,1818 H Street, NW,
Washington DC 20043
Tél: (202) 473 4571 – Fax: (202) 473 8216 – E-mail: [email protected]
Belgique
39.
Dr Jacques Walter LARUELLE
Chargé de Programmes, Ministère des Affaires étrangères, Direction générale de la Coopération au
Développement, rue Brederode 6 – B-1000 Bruxelles, Belgique
Tel : (0032) 2 519 07 52 – Fax : (0032) 2 519 05 70 – E-mail : [email protected]
Canada
40.
Mme Catherine BERARD
Agent principal de développement, Agence canadienne de Développement International, 200,
promenade du portage, Gatineau (Québec), Canada K1A, 0G4
Tel : (819) 994 4194 – Fax : (819) 997 5453 – E-mail : [email protected]
France
41.
Dr Jean Christophe DEBERRE, Directeur , Département du Développement de la Politique Internationale,
Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP, France
Tél : (331) 53 69 31 87 – Fax : (331) 45 51 60 12
42.
Dr Frédéric GOYET
Chef du Bureau de la Santé, Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP,
France
Tél : 015 369 3186 – Fax : 33 015 369 3719 – E-mail : [email protected]
43.
M. Hervé D’ORIANO
Bureau de la Santé ,Politique hospitalière, Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris
07 SP, France, Tél : 33 015 369 4333 – Fax : 33 015 369 3719 – E-mail :
[email protected]
44. M. Antonio ORTIZ s/c Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP, France,
Tél : (331) 53 69 31 87 – Fax : (331) 45 51 60 12
45.
Mme Sandrine BOUCHER s/c , Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP,
France, Tél : (331) 53 69 31 87 – Fax : (331) 45 51 60 12
46.
M. Philippe ETIENNE s/c , Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP,
France, Tél : (331) 53 69 31 87 – Fax : (331) 45 51 60 12
16
47.
Mme France AGID s/c , Ministère des Affaires étrangères, 20, rue Monsieur, 75007 Paris 07 SP, France,
Tél : (331) 53 69 31 87 – Fax : (331) 45 51 60 12
48.
Dr Christian BAILLY
Expert, Coordonnateur CIRE, Cellule Inter-régionale d’Epidémiologie Ouest, Ministère des Affaires
étrangères, 20, rue d’Isly, CS 84224, 35042 Renne Cedex, France
Tel : (332) 99 35 29 60 - Fax : (331) 99 35 29 61 – E-mail : [email protected]
Kowait/Kuweit
49.
Dr A.M. BAHMAN
Agricultural Advisor, P.O. Box 2921 Safat, 13030 Kuwait, Tel: (965) 2999186/7 –
Fax: (965) 2999190/1 – E-mail: [email protected]
50.
Mr Qais A.M.S. AL JOAN
Technical Advisor, P.O. Box 2921 Safat, 13030 Kuwait, Tel: (965) 2999161 –
Fax: (965) 2999190/1 – E-mail: [email protected]
Luxembourg/Luxemburg
51.
M. Robert HEMMER
Chef du Service National des Maladies Infectieuses, Centre Hospitalier du Luxembourg, 4, Rue Barble, L1210, Luxembourg, Tel: (352) 4411 3091 – Fax : (352) 4412 79 – [email protected]
Pologne/Poland
52.
Mme Weglenska MAGDALENA
Stagiaire à l’Ambassade de Pologne à Paris, 1-3 rue de Talleyrand, Paris 75007, Tel: (331) 43 17 34 04 E-mail: [email protected] or [email protected]
Arabie Saoudite/Saudi Arabia
53.
Mr Hasan ALATTAS
Director General, Technical Department, The Saudi Fund for Development, P.O. Box 1887, Riyadh
11441, Saudi Arabia
Tel: +9661 464 1928 – Fax: +966 1464 7450- E-mail: [email protected]
54.
Mr Saud-ALFANTOUKH
Director General, Control & Audit Department, The Saudi Fund for Development , Kingdom of
Saudi Arabia, P.O. Box 50483, Riyadh 11523, Saudi Arabia
Tel: +9661 46 40 723 – Fax: +9661 46 47 450 – E-mail: [email protected]
Royaume-Uni /United Kingdom
55.
Ms Josephine ASIEDU
Deputy Policy Analyst, Global Health Partnerships Team, Policy Division, Department of International
Development (DFID), 1 Palace Street, SW1E 5HE, London, England, United Kingdom, Tél. : 0207 023
0891, E-mail: [email protected]
56.
Prof. David MOLYNEUX
Director Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine, Pembroke Place
Liverpool L3 5QA, UK, Tel: (44) 151 705 3291 – Fax: (44) 151 709 0354 –
E-mail: [email protected]
17
ONGD/NGDO
Christoffel Blindenmission (CBM)
57.
Dr Adrian Dennis HOPKINS
Medical Advisor, Regional Office, P. O. Box 58004-00200, Nairobi, Kenya
Tél: +254 3751 654/798 – Fax: 254 20 374 0305- - E-mail: [email protected];
[email protected]
58.
Mr Fasil Chane BIZUNEH
NGDO CDTI Coordinator, P.O. Box 58004-00200, Nairobi, Kenya, Tel: (254) 722 52 7953 –
Fax: (254) 20 374 0305 – E-mail: [email protected]
The Carter Center
59.
Dr Moses N. KATABARWA
Epidemiologist, River Blindness, Lymphatic Filariasis & Schistosomiasis Program, 453 Freedom
Parkway, One Copenhill, Atlanta, GA 30307 USA, Tel : 770 488 4511 – Fax : 770 488 4521 –
E-mail : [email protected]; [email protected]
60.
Mrs Nicole KRUSE
Chief Development Officer, The Carter Center, One Copenhill, Atlanta, GA 30307, USA
Tel: (404) 420 5132 – Fax: (404) 688 1701 – E-mail: [email protected]
61.
Dr Frank RICHARDS
Technical Director – River Blindness, Lymphatic Filariasis & Schistosomiasis Program, 453 Freedom
Parkway, One Copenhill, Atlanta, GA 30307 USA, Tel: 770 488 4511 –
Fax: 770 488 4521 – E-mail: [email protected], [email protected]
Helen Keller International (HKI)
62.
Ms Nancy J. HASELOW
Director of Onchocerciasis Programs, HKI Regional Office for Africa, 11 Nord Foire, Azur-Dakar, P.O.
Box 29898, Dakar-Yoff, Senegal, Tel: (221) 820 74 77 – Fax: (221) 869 10 63/64/68– E-mail:
[email protected]
63.
Mrs Alix DE NICOLAY
Director of Development, Helen Keller International, Paris, France , Tel/Fax: (331) 47 64 11 30 – Email: [email protected]
Interchurch Medical Assistance (IMA)
64.
Mr Paul DERSTINE
President, Interchurch Medical Assistance (IMA), 500 Main Street, Old Main Building, P.O. Box 429,
New Windsor, Maryland 21776, USA, Tel: +1 410 635 8720 – Fax: + 1 410 635 8726 –
E-mail: [email protected]
Light for the World
65.
Ms. Agnes HAUSER
A-1120 Wien, Darnautgasse 13/5, Vienna, Austria, Tel: +43 1 810 13 00-16 –
Fax: +43 1 810 13 00-15 - E-mail: [email protected]
18
Lions Club International Foundation
66.
Mme Dominique COSTE
Présidente Commission Sight First Afrique Centrale & Océan Indien, Représentante de la LCIF pour les
Programmes de Santé, B.P. 4794, Yaoundé, Cameroun, Tel : (237) 220 50 07 –
Fax : (237) 221 55 67 – E-mail : [email protected]
Merck & Co. Inc.
67.
Mr Ken GUSTAVSEN
Manager, Global Product Donations, Merck & Co., Inc., Whitehouse Station, NJ 08889, United States
of America, Tel: (+1) 908 423 3088 – Fax: (+1) 908 423 1987 –
E-mail: [email protected]
Mectizan Donation Program
68.
Dr Bjorn THYLEFORS
Director, Mectizan Donation Program, 750 Commerce Drive, Decatur, 30030 GA, United States of
America, Tel: + 1 404 371 1460 – Fax: +1 404 371 1138- E-mail: [email protected]
69.
Dr Mary ALLEMAN
Associate Director, Mectizan Donation Program, 750 Commerce Drive, Suite 400, Decatur, GA, 30030,
United States of America , Tel: + 1 404 371 1460 – Fax: +1 404 371 1138E-mail: [email protected]
The Micronutrient Initiative
70.
Dr Julia MOORMAN
95, Oxford Road, Rosebank, Johannesburg 20946, South Africa, P.O. Box 2927, Houghton, 2041, South
Africa, Tel: 27 11 327 6292 – Fax: 27 11 327 6286 – E-mail: [email protected]
71.
Professor Claire SITA
The Micronutrient Initiative Coordinator, A 97 Q Longo, Cité Kauka C de Kalamu, Kinshasa,
Democratic Republic of Congo, c/o Dr Julia Moorman
Tel: (243) 81 50 49 800 – E-mail: [email protected]
Mitosath
72.
Mrs Francisca OLAMIJU
Executive Director, 605 Hospital Place, Opposite Green Valley, Suites, GRA, Jos Plateau State, Nigeria,
Tel: (234) 073 464794 – Fax: (234) 464792 – E-mail: [email protected] or
[email protected]
Organisation pour la Prévention de la Cécité (OPC)
73.
Prof. Yves POULIQUEN
Président, Organisation pour la Prévention de la Cécité (OPC), 17, Villa d’Alésia, 75014 Paris, France,
Tél : (331) 44 12 41 90/97 - Fax : (331) 44 12 23 01
74.
Dr André-Dominique NEGREL
Directeur Exécutif, Organisation pour la Prévention de la Cécité (OPC), 17, Villa d’Alésia, 75014 Paris,
France
Tél : (331)44 12 41 93 - Fax : (331) 44 12 23 01 – E-mail : [email protected]
19
75.
Dr Jean François CECCON
Directeur des Programmes, Organisation pour la Prévention de la Cécité (OPC), 17, Villa d’Alésia,
75014 Paris, France
Tél (331) 44 12 41 90/97 - Fax : (331) 44 12 23 01 – E-mail : [email protected]
76.
Dr Seydou MARIKO
Coordonnateur pour la Prévention de la Cécité pour l’Afrique de l’Ouest, Organisation pour la
Prévention de la Cécité (OPC), OPC/BRAO, B.P. 1764, Bamako, Mali
Tél : (223) 229 63 39 –E-mail : [email protected]
77.
Dr Philippe GAXOTTE
Administrateur et Conseiller de l’onchocercose, Organisation pour la Prévention de la Cécité (OPC), 27,
rue Vaneau, 75007 Paris, France
Tél : (331) 47 05 17 64 – E-mail : [email protected]
78.
Mme Hayet GHALEM-KSOURI
Assistante du Directeur des Programmes, Organisation pour la Prévention de la Cécité (OPC), 17, Villa
d’Alésia, 75014 Paris, France
Tél : (331) 44 12 41 98 - Fax : 44 10 23 01 - E-mail :[email protected]
79.
Mme Dominique BERTRAND
Assistante de Direction, Organisation pour la Prévention de la Cécité (OPC), 17, Villa d’Alésia, 75014
Paris , France
Tél : (331) 44 12 41 90/97 - Fax : (331) 44 12 23 01
80.
Mme Célia WARIN
Assistante anglophone, Organisation pour la Prévention de la Cécité (OPC), 17 villa d’Alésia, 75014,
Paris, France
Tél : (331) 44 12 41 90/97 - Fax : (331) 44 12 23 01 - E-mail : [email protected]
81.
Mme Laura JOUANIN
Secrétaire, Organisation pour la Prévention de la Cécité (OPC), 17 villa d’Alésia, 75014, Paris, France,
Tél : (331) 44 12 41 90/97 - Fax : (331) 44 12 23 01
Sight Savers International (SSI)
82.
Ms Catherine CROSS
Manager, International Programmes, Sight Savers International, Grosvenor Hall, Bolnore Road,
Haywards Heath, RH16 4BX, United Kingdom, Tel: +44 1444 446600 – Fax: +44 1444 446677 – Email: [email protected]
83.
Mr Simon BUSH
Regional Director, West Africa, Sight Savers International, 58 Patrice Lumumba Road, P.O. Box KIA
18190, Airport, Accra, Ghana, Tel: + 233 21 774210/784702 – Fax: +233 21 774209 –
E-mail: [email protected]
84.
Dr Johnson NGOROK
Deputy Regional Director, East, Central, and Southern Africa, Sight Savers International, P.O. Box
34690, 00100 GPO, Nairobi, Kenya, Tel: +254 722 56 78 97 ou 254 20 606970/601204 – Fax: +254 20
609623 – E-mail: [email protected]
20
United Front Against Riverblindness
85.
Dr Daniel SHUNGU
Chief Executive Director, 13 Carnation Place Lawrenceville, New Jersey 08648/USA, United States of
America, Tel: (609) 771 3674 or (609) 954 3398 – Fax : (609) 530 1594,
E-mail: [email protected]
PARTICIPANTS DE DROIT / EX-OFFICIO PARTICIPANTS
IRD
86.
Professeur Jean-François GIRARD
Président, Institut de Recherche pour le Développement (IRD), 213, rue Lafayette, 75010 Paris Cedex
10, France
87.
M. Serge CALABRE, Directeur Général, Institut de Recherche pour le Développement (IRD), 213, rue
Lafayette, 75010, Paris Cedex 10, France, Tél : (331) 48 03 77 01 –
Fax : (331) 40 36 26 24 – E-mail : [email protected]
88.
M. Jacques CHARMES
Directeur Département Société et Santé, Institut de Recherche pour le Développement (IRD), 213, rue
Lafayette, 75010, Paris Cedex 10, France, Tél : (331) 48 03 77 77 – Fax : (331) 40 36 25 24
89.
Mme Bernadette MURGUE
Chargée de Mission, Département Société et Santé , Institut de Recherche pour le Développement (IRD),
213, rue Lafayette, 75010, Paris Cedex 10, France
Tel : (331) 48 03 77 09 – Fax : (31) 48 03 77 09 – E-mail : [email protected]
90.
M. Vincent ROBERT
Chargé de mission , Département Sociétés et Santé, Institut de Recherche pour le Développement (IRD),
213 rue Lafayette, 75480 Paris Cedex 10
Tél : (331) 40 79 35 13 – E-mail : [email protected]
91.
Dr Michel BOUSSINESQ
Chercheur, Membre CCT/APOC, Institut de Recherche pour le Développement (IRD/DSS), 213 rue
Lafayette, 75480 Paris Cedex 10, France, Tel : (331) 42 49 38 15 - E-mail : [email protected]
92.
Dr Christian LEVEQUE
Directeur de Recherche, 1, rue de Marnes, 92410, Ville d’Avray, Institut de Recherche pour le
Développement (IRD), Paris Cedex 10, France, Tél : (331) 41 15 01 40 – [email protected];
[email protected]
93.
Dr Bernard PHILIPPON
Directeur de Recherches Emérite, Institut de Recherche pour le Développement (IRD), 213, rue Lafayette,
75010 Paris, Cedex 10, France, Tél /Fax: (331) 40 44 94 04 –
E-mail : [email protected]
94.
Dr Bernard SURUGUE
Directeur de Recherche, 32, avenue Henri Varagnat, 93140 Bondi, Paris, France
Tél : (331) 48 02 59 72 – Fax : (331) 48 02 56 52 – E-mail : [email protected]
21
95.
Dr François SIMONDON
Directeur UR, Epidémiologie et Prévention : Environnement et efficacité des interventions, Institut de
Recherche pour le Développement (IRD), Centre de Montpellier, 34032, Montpellier Cedex, France,
Tél : (33) 4 67 41 61 71 – Fax : (33) 4 67 41 61 62 – E-mail : [email protected]
96. Mme FAVIER M. Noëlle
Directrice de la Communication, Institut de Recherche pour le Développement (IRD), 213, rue Lafayette,
75010, Paris Cedex 10, France, Tél : (331) 48 03 77 47 – Fax : (331) 40 34 69 13
Tél : (331) 48 03 77 48 – Fax : (331) 48 03 77 42 – E-mail : [email protected]
97.
Mlle Sophie NUNZIATI
Attachée de Presse, Institut de Recherche pour le Développement (IRD), 213, rue Lafayette, 75010,
Paris Cedex 10, France, Tél : (331) 48 03 75 19 – Fax : (331) 40 36 24 55 –
E-mail : [email protected]
OMS/SIEGE/GENEVE – WHO/HQ/GENEVA
Bureau du Directeur général de l’OMS/Office of the Director General
98.
Dr Catherine LE GALÈS-CAMUS
Assistant Director-General, Noncommunicable Diseases and Mental Health, WHO/Geneva, 20 Avenue
Appia, CH-1211 Geneva 27, Switzerland, Tel: (4122) 791 12999 – E-mail: [email protected]
99.
Dr Lorenzo SAVIOLI
Director, Department of Control of Neglected Tropical Diseases, WHO/Geneva, 20 Avenue Appia,
CH-1211 Geneva 27, Switzerland,Tel: (4122) 791 2664 – Fax: (4122) 791 4869 – E-mail:
[email protected]
100. Dr Jan H.F. REMME
Coordinator, Science Strategy and Knowledge, Special Programme for Research and Training in
Tropical Diseases, WHO/Geneva, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland, Fax : 4122
7914854, Tél : 4122 791 3815, e-mail : [email protected]
101. Dr Janis Karlin LAZDINS-HELDS
Acting Coordinator, Product Development and Evaluation, Special Programme for Research and
Training in Tropical Diseases, Geneva, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland, Tél :
4122 791 3818 - Fax : 4122 791 4854 - E-mail : [email protected]
102. Dr Annette KUESEL
Manager,CPRC, OMS/TDR, WHO, 20 Avenue Appia, 1211 Geneva 27, Suwitzerland
Tel: (4122) 791 1541 – Fax: (4122) 791 4774 – E-mail: [email protected]
Bureau du Conseiller Juridique/Legal Counsel
103. Mr Gian Luca BURCI
Conseiller juridique, Organisation Mondiale de la Santé, 20, Avenue Appia, CH 1211, Genève 27,
Suisse, Tel: (4122) 791 4754 – Fax: (4122) 791 4158 – E-mail: [email protected]
104. M. Claude Henri VIGNES
Bureau du Conseiller Juridique, CH 1211 Genève 27, Suisse, Tel: (4122) 791 2638,Fax: (4122) 791 4158
22
Prevention of Blindness and Deafness / Department of Chronic Diseases and Health Promotion
105. Dr. Serge RESNIKOFF
Coordinator, Chronic Diseases Prevention and Management, (CPM), Department of Chronic Diseases
and Health Promotion, (CHP), World Health Organization, 20 Avenue Appia, 1211 Geneva 27,
Switzerland , Tel: +41-22-791-4124 - FAX: +41-22-791-4771 - E-mail: [email protected]
106. Dr Tony UKETY
NGDO Coordinator for Onchocerciasis Control, Chronic Diseases Prevention and Management (CPM),
Department of Chronic Diseases and Health Promotion, (CHP), World Health Organization, 20 Avenue
Appia, 1211 Geneva 27, Switzerland, Tel: +41-22-791-1450 –
Fax: +41-22-791-4772 - E-mail: [email protected]
CBF/ACT
107. Mr Brendan DALY
Chief Accountant, WHO/CBF/ACT, 20 Avenue Appia, CH-1211 Geneva, Switzerland
Tel: (+4122) 791 2278 – Fax: (+4122) 791 4164 – E-mail: [email protected]
OMS/AFRO -WHO/AFRO
108. Dr James N. MWANZIA
Director, Division of Communicable Diseases, P.O. Box BE773, Belvedere, Harare, Zimbabwe
Tel: (263) 4 700 026 - Fax: (263) 4 746127 ou (263) 11 420 588 – E-mail: [email protected]
MDSC
109. Prof. Brehima KOUMARE
Directeur a.i. , Centre de Surveillance Pluripathologique (MDSC), 01 B.P. 549 Ouagadougou 01,
Burkina Faso, Tel: (226) 50 34 38 18 – (226) 50 34 28 75 – E-mail: [email protected]
SECRETARIAT OMS/ WHO SECRETARIAT
110. Dr Uche AMAZIGO
Directrice du Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou
01, Burkina Faso, Tel : (226) 34 29 53 – Fax : (226) 34 28 75 –
E-mail : [email protected]
111. Dr Laurent YAMEOGO
Manager du Programme, Coordonnateur du Bureau du Directeur, Programme Africain de Lutte contre
l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso
Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : [email protected]
112. Dr Mounkaïla NOMA
Chef, Unité d’Elimination du Vecteur, Programme Africain de Lutte contre l’Onchocercose (APOC) 01
B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 –
Fax : (226) 34 28 75 – E-mail : [email protected]
23
113. M. Honorat ZOURE
Responsable chargé de la Biostistique, Informatique et Cartographie (BIM), Programme Africain de
Lutte contre l’Onchocercose (APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso
Tel : (226) 34 29 53 – Fax : (226) 34 28 75 – E-mail : [email protected]
114. M. K. AGBLEWONU
Administrateur du Budget et Finances, Programme Africain de Lutte contre l’Onchocercose (APOC) 01
B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 –
Fax : (226) 34 28 75 – E-mail : [email protected]
115. M. Yaovi AHOLOU
Chargé d’Administration, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549,
Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 – Fax : (226) 34 28 75 –
E-mail : [email protected]
116. M. Samuel Bamfo ODAME
Traducteur, APOC, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549,
Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 – Fax : (226) 34 28 75 –
E-mail : [email protected]
117. M. Abdoulaye DARIBI
APOC/AFRO Liaison Office, World Health Organization, 20 Avenue Appia, 1211 Geneva 27,
Switzerland, Tel : (4122) 7913883 – Fax : (4122) 791 4190 – E-mail : [email protected]
118. Mme Edith OUEDRAOGO
Assistante Administrative chargée des Réunions, Programme Africain de Lutte contre l’Onchocercose
(APOC) 01 B.P. 549, Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 –
Fax : (226) 34 28 75 – E-mail : [email protected]
119. Mme Agnès DRABO
Assistante Administrative, Programme Africain de Lutte contre l’Onchocercose (APOC) 01 B.P. 549,
Ouagadougou 01, Burkina Faso, Tel : (226) 34 29 53 – Fax : (226) 34 28 75 –
E-mail : [email protected]
TCC
120. Prof Ekanem BRAIDE
Vice Chancellor, Cross River University of Technology, Calabar, Chair of TCC, P.O. Box 3679,
Calabar, Nigeria, Tel: (234) 080 33 41 68 42, Fax: (234) 087 230 914/087 230 911, E-mail:
[email protected]; [email protected]; [email protected]
121. Prof Deborah MCFARLAND
Associate Professor, Department of International Health, Rollins School of Public Health, Emory
University, TCC member, 1518 Clifton Road, Atlanta, Georgia, 30322, Tel: (1) 404 727 7849 - Fax: (1)
404 727 4590, E-mail: [email protected]
24
EQUIPE D’EVALUATION EXTERNE D’APOC ET SIZ/APOC AND SIZ EXTERNAL
EVALUATION TEAM
122. Dr Eleuther TARIMO
APOC External Evaluation Team Leader, P.O. Box 33277, Dar-es-Salaam, Tanzania
Tel: (255) 748 318574/ (255) 222 73505/(255) 222 73568- E-mail: [email protected] or
[email protected]
123. Prof. Adenike ABIOSE, SIZ External Evaluation Team Leader, P.O. Box 29771, Secretariat Main
Office, Ibadan, Oyo State, Nigeria
Tel/Fax: (234) 2 8107434 – E-mail: [email protected]; [email protected];
[email protected]
124. Dr André YEBAKIMA
Evaluateur/CCS, Centre de démoustication, BP 697 97200, Fort de France (Martinique)
Tél : 0596598544 - Fax : 0596702646 - E-mail : [email protected]
INTERPRETES/INTERPRETORS
125. M. Christian STENERSEN
Interpretor, Les Rossanets, F-01170 Segny (France)
Tel : (334) 5041 7880
126. Mlle Geneviève CLEMENT
Interprète, 80, rue de Meyrin, F-01210 Ferney-Voltaire, France (région de Genève)
Tel : (334) 50 40 76 50 127. Ms Mara SFREDDO
Interprète, 11, Ch. de la Rochette, 1202, Genève, Suisse
Tel : 4122 740 4851 - E-mail : [email protected]
128. Mme Madeleine GIROT
Interprète, 4, rue des Fossés, Saint Maral, 75005, Paris, France
Tél : (331) 43 37 81 87 –- E-mail : [email protected]
OBSERVATEURS/OBSERVERS
Burkina Faso
129. Dr Mété BONKOUNGOU
Directeur Régional de la Santé des Hauts-Bassins, entomologiste national, Programme de lutte contre
l’onchocercose, 01 BP 1508, Bobo-Dioulasso 01, Burkina Faso
Tél : (226) 20 97 14 21, Mobile 70 25 27 51, E-mail : [email protected]
DANIDA
130. Dr Erling M. PEDERSEN
Technical Advisor for Danida, DBL-Institute for Health Research and Development, Jaegersborg Allé 1
D, DK-2920 Charlottenlund, Denmark
Tel: +45 77 32 77 63 (direct)/+45 77 32 77 32 (switchboard) – Fax: + 45 77 32 77 33 – E-mail:
[email protected]
25
Ghana
131. Dr John GYAPONG
Director of Research, Programme Manager, LF and Oncho, Health Research Unit, Ghana Health Service,
Oncho Control Programme, P.O. Box GP 184, Accra, Ghana
Tel: (233) 21 68 10 85 – Cel: (233) 24 26 50 81 – Fax: (233) 21 22 67 39 – E-mail: [email protected]
Guinée Conakry
132. Dr Nouhou Konkouré DIALLO
Coordonnateur National du Programme National de lutte contre l’onchocercose et la Cécité (PNLO),
Ministère de la Santé publique, Programme Onchocercose – Cécité, B.P. 585, Conakry, République de
Guinée
Tél : (224) 25 3371 - Fax : (224) 433707 - E-mail : [email protected]
Mali
133. Dr Mamadou TRAORE, Coordonnateur National du Programme de lutte contre l’onchocercose,
Direction nationale de la Santé, Bamako, Mali
Tel : (223) 222 64 97 – Fax : (223) 223 36 74 - E-mail : [email protected] ou [email protected]
134. Dr Moussa SOW, Entomologiste national, Direction nationale de la Santé, B.P. 233, Bamako, Mali
Tel : (223) 222 29 21 – Fax : (223) 223 36 74 - E-mail : [email protected]
Organisation Ouest Africaine de la Santé/West African Health Organisation
135. Dr Kabba T. JOINER
Director General, West African Health Organisation, 01 B.P. 153, Bobo-Dioulasso, Burkina Faso
Tel: (226) 2097 1560 – Fax: (226) 2097 2972 – E-mail: [email protected] or
[email protected]
136. Prof. Kayode ODUSOTE
Director, Division of Human Resources Development, West African Health Organization 01 B.P. 153,
Bobo-Dioulasso, Burkina Faso, Tel: (226) 2097 0097 – Fax: (226) 2097 5772 –
E-mail: [email protected]; or [email protected];[email protected]
AA/Mtg
19.12.2005
26
Annex 2
AGENDA
JAF11, Paris 6-9 December 2005
1.
Opening of the session
2.
Election of Officers
3.
Adoption of Agenda
4.
Reflections of the Committee of Sponsoring Agencies
5.
Progress Report of the World Health Organisation
6.
Report of the Technical Consultative Committee (TCC)
7.
Report of the NGDO Coordination Group for Onchocerciasis control, including support of the
group to APOC activities
8.
APOC External Evaluation Report (2001-2004)
9.
Mid-term evaluation report on activities of the Special Intervention Zones (SIZ) and evaluation of
the efficacy of the onchocerciasis surveillance systems in the ex-OCP countries
10.
Vision for the future of Onchocerciasis Control in Africa
11.
Interventions of the Presidents of the Organization for the Prevention of Blindness (OPC) and the
Research Institute for Development (IRD), France
12.
Country reports:
(i)
(ii)
(Congo, Nigeria, Tanzania, Cameroon, Central African Republic, Uganda, Malawi, Sudan,
Equatorial Guinea, Democratic Republic of Congo, Liberia, Chad, Ethiopia, Burundi, Angola)
(Gabon, Mozambique, Rwanda, Kenya)
13.
Consideration of National plans and Project proposals
14.
Operational research and MACROFIL
15.
Community-Directed Interventions (CDI): conclusions and recommendations of special meetings
on CDIs and the integration of community-based programmes
16.
17.
(i)
(ii)
Sustainability of CDTI projects
Updates on project evaluation
Monitoring the implementation of sustainability plans
Report on cost per treatment with ivermectin
27
18.
Additional health interventions using CDTI as a vehicle
19.
Independent participatory monitoring of CDTI projects
20.
Phase II of the long-term impact assessment of APOC operations
21.
Audit report
22.
Plan of Action and Budget for 2006
23.
Financing of the African Programme for Onchocerciasis Control (APOC)
(i)
(ii)
(iii)
(iv)
Country contributions
NGDO contributions
Report of the World Bank
Pledging of Donor contributions
24.
Information on activities in the Special Intervention Zones (SIZ) of the ex-OCP, non-SIZ areas,
and the Multi-Disease Surveillance Centre (MDSC) of Ouagadougou
25.
Other matters
26.
Date and place of the twelfth session
27.
Consolidation of JAF11 conclusions and decisions and drafting of final communiqué
28.
Final approval of the conclusions and decisions and adoption of the final communiqué
29.
Closure of the eleventh session
DIR/APOC/08.11.05